Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenXSWX:BIIB 74 EV-to-OCF is 12.74 as of Jul. 25, 2026, which is 2% below its 10-year median of 13.03. GuruFocus rates XSWX:BIIB with a GF Score™ of 74/100 and a GF Value™ of CHF164.93. The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Biogen ranks worse than 54.02% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Biogen's Enterprise Value is CHF26,250 Mil.
Biogen's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was CHF2,060 Mil. Therefore, Biogen's EV-to-OCF for today is 12.74.
The historical rank and industry rank for Biogen's EV-to-OCF or its related term are showing as below:
XSWX:BIIB'
s EV-to-OCF Range Over the Past 10 Years
Min: 6.05 Med: 13.03 Max: 32.02
Current: 12.4
During the past 13 years, the highest EV-to-OCF of Biogen was 32.02. The lowest was 6.05. And the median was 13.03.
XSWX:BIIB's EV-to-OCF is ranked worse than 54.02% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.41
vs XSWX:BIIB: 12.40
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-25), Biogen's stock price is CHF173.46.
Biogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF7.475. Therefore, Biogen's PE Ratio (TTM) for today is 23.21.
Biogen (XSWX:BIIB) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biogen's share price for today is CHF173.46.
Biogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF7.475.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biogen EV-to-OCF Related Terms
Biogen EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Biogen's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BIIB vs OGN, AMRN, SCLX: EV-to-OCF Comparison
For the Drug Manufacturers - General subindustry, Biogen's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Biogen's EV-to-OCF falls into.
Biogen's current Enterprise Value is CHF26,250 Mil.
Biogen's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,060 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (XSWX:BIIB) has a EV-to-OCF of 12.74 as of Jul. 25, 2026. This is near median its historical median of 13.03. Over the past decade, Biogen's EV-to-OCF has ranged from 6.05 to 32.02. According to the industry distribution chart, Biogen ranks #544 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 54%.
Is Biogen's EV-to-OCF too high?
Biogen's current EV-to-OCF of 12.74 is near median its 10-year median of 13.03. Over the past 10 years, this metric has ranged from a low of 6.05 to a high of 32.02. The Drug Manufacturers industry median EV-to-OCF is 10.41. Biogen's value of 12.74 is 22.4% above this industry median. Based on the distribution chart, Biogen ranks #544 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biogen has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's EV-to-OCF compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #544 out of 1007 companies for EV-to-OCF. This places Biogen in the lower half of its industry. The industry median EV-to-OCF is 10.41. Biogen's value of 12.74 is 22.4% above this benchmark. Historically, Biogen's own EV-to-OCF has ranged from 6.05 to 32.02 over the past decade. While the company's 10-year median is 13.03 vs. the industry median of 10.41, Biogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.41, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current EV-to-OCF of 12.74 is 22.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current EV-to-OCF is 12.74, which is near median its own 10-year median of 13.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current EV-to-OCF of 12.74. The stock's GF Value™ is CHF164.93, compared to a current price of CHF173.46 — trading 5.2% above its estimated fair value. The current EV-to-OCF is 12.74, which is near median its 10-year median of 13.03 and 22.4% above the Drug Manufacturers industry median of 10.41. Biogen's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current EV-to-OCF is 12.74 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (XSWX:BIIB) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of CHF173.46 is trading 5.2% above its estimated GF Value™ of CHF164.93.
Key valuation signals for XSWX:BIIB:
EV-to-OCF: 12.74 (near median its 10-year median of 13.03)
GF Value™: CHF164.93 vs. price of CHF173.46 (5.2% above fair value)
Industry Position: 22.4% above the Drug Manufacturers median (#544 of 1007)
No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
74GF Score
Get the complete analysis for XSWX:BIIB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIIB has been successfully added to your 
